U se of percutaneous transluminal renal angioplasty and stenting to treat refractory hypertension secondary to renal artery stenosis has increased dramatically. In Medicare beneficiaries, between 1996 and 2000, the number of renal interventions increased from 7660 to 18 520; half of these were performed by cardiologists. 1 Approximately one third of the treated patients failed to show improvement in hypertension after the procedure. 2 Biomarkers that would identify patients likely to respond to revascularization would enhance patient selection and improve cost effectiveness.
Brain natriuretic peptide (BNP) is a neurohormone released from the ventricular myocardium in conditions that cause myocardial cell stretching such as congestive heart failure and pulmonary embolism. [3] [4] [5] This neurohormone, which has a serum half-life of Ϸ20 minutes, has been shown to directly correlate with pulmonary capillary wedge pressure. 6, 7 BNP is also considered a good predictor of major cardiovascular events and sudden death in patients with unstable angina, myocardial infarction, and ischemic cardiomyopathy. 8 -10 Although most of the circulating BNP is synthesized and released from ventricular myocytes, its most important physiological actions occur at the kidney level not only during conditions of health but also in pathological states. 11, 12 BNP promotes diuresis, natriuresis, and arterial vasodilation and antagonizes renin activity. 3 In vitro data have also shown that angiotensin II may directly induce the synthesis and release of BNP, and an animal study has suggested that BNP mRNA is significantly upregulated 6 hours after clipping of the renal artery. 13, 14 Theoretically, BNP may be increased in patients with renovascular hypertension, a condition known to promote activation of the renal angiotensin system and the release of angiotensin II. [15] [16] [17] The aims of the present investigation were to determine whether BNP may be increased in patients with renal artery stenosis, whether successful renal artery revascularization would affect BNP levels, and whether elevated BNP levels might predict which patients would have a blood pressure response after successful renal artery revascularization with a stent.
Methods

Patient Selection
Thirty-four consecutive patients with significant renal artery stenosis (Ն70% diameter stenosis) by angiography were prospectively included in the study. Seven initially screened patients were excluded from the protocol because of (1) congestive heart failure exacerbation and left ventricular dysfunction (ejection fraction Ͻ40%; nϭ3), (2) recent (within 6 months) myocardial infarction and/or acute coronary syndromes (nϭ2), and (3) chronic renal insufficiency (creatinine Ն2 mg/dL; nϭ2).
All renal artery stenoses were atherosclerotic ostial stenoses (within 5 mm of the origin of the vessel). Eighteen patients had unilateral renal artery stenosis; 9 patients had bilateral renal artery stenosis. The investigators enrolled all patients in the protocol without knowledge of the patients' BNP levels. The study was approved by the Investigational Review Board of the Ochsner Clinic Foundation. All patients enrolled in the protocol signed informed consent.
Procedure
All patients were pretreated with aspirin for Ն24 hours before the procedure, and aspirin was continued indefinitely. The renal stent placement procedure has been described previously. 18 All patients had BNP measured on 4 occasions: 2 to 7 days before the procedure (nϭ23), within 24 hours of the intervention (nϭ27), 1 day after the intervention (nϭ27), and 7 days to 2 months after the intervention (nϭ25). Serum creatinine was measured 24 to 48 hours before and within 1 week after the renal artery intervention. Blood pressures were measured according to the guidelines proposed by the AHA, 19 and the number of antihypertensive medications before the procedure, at hospital discharge, and at follow-up was recorded.
The operator performing the procedure visually estimated diameter stenosis. Kidney length was calculated by measuring the pole-topole kidney shadow during the parenchymal phase of renal angiography with computerized quantitative angiography (Image Comm Systems Inc). The estimated glomerular filtration rate (eGFR) was calculated with the Cockroft-Gault equation 20 and standardized in each patient to 1.73 m 2 body surface. The investigators obtained these measurements without knowledge of the patients' BNP levels or blood pressures.
For determination of BNP, all blood samples were collected by venipuncture into EDTA tubes. The blood samples were kept at room temperature and analyzed within 4 hours with the Biosite assay (Biosite Diagnostics). For the present investigation and similar to previous studies, BNP levels were dichotomized through the use of published criteria for BNP normality at Յ80 pg/mL. 9, 21 Definitions Hypertension was defined as systolic blood pressure Ն140 mm Hg and/or diastolic blood pressure Ն90 mm Hg. Refractory hypertension was defined as a blood pressure that could not be reduced to Ͻ140/90 mm Hg with a 3-drug regimen. Improvement in hypertension (blood pressure responders) was defined as diastolic blood pressure Ͻ90 mm Hg and systolic blood pressure Ͻ140 mm Hg on the same or reduced number of antihypertensive medications or a reduction in diastolic blood pressure of Ն15 mm Hg on the same or reduced number of antihypertensive medications. These definitions follow the guidelines for reporting clinical trials in renal artery revascularization. 22 Angiographic success was defined as a residual diameter stenosis of Ͻ30% after stent placement. Procedural success was defined as angiographic success and the absence of a major complication during hospitalization. Major complications included death, myocardial infarction, stroke, bleeding requiring transfusion, and need for hemodialysis or surgery. A significant decrease in BNP was defined as a decline in this peptide of Ͼ30% from baseline in patients with an elevated baseline BNP of Ͼ80 pg/mL.
Study End Points
The primary end point of this study was to compare the baseline and posttreatment BNP levels. The secondary end point was to determine whether the baseline BNP level correlated with clinical improvement in hypertension at follow-up.
Statistical Analysis
Categorical variables are reported as frequencies and percentages; continuous variables, as meanϮSD. However, when the variable was significantly skewed or had extreme values, the median (25th to 75th percentiles) was reported. Student's t tests or Wilcoxon's 2-sample tests were used to compare continuous variables; 2 tests were used to compare categorical variables.
Bivariate correlation analysis was performed with Pearson's or coefficients to investigate whether percent diameter stenosis was correlated with BNP and with hypertension improvement and whether BNP and eGFR were correlated with hypertension improvement. The correlation of BNP with hypertension improvement at follow-up was then assessed independently with multivariate analysis (partial correlation analysis), with correction for eGFR (a continuous variable), eGFR Ͻ60 mL · min Ϫ1 · m Ϫ2 (a categorical variable), creatinine, and preprocedural diastolic blood pressure (SPSS version 11.0, SPSS Inc). Differences at the level of PϽ0.05 (2 tailed) were considered statistically significant.
Results
The baseline clinical characteristics of the patient population are shown in Table 1 . The angiographic and procedural success rates were 100%. There were no procedural complications or in-hospital major cardiovascular events. After successful renal stent revascularization, the serum levels of BNP fell from 187 pg/mL (25th to 75th percentiles, 89 to 306 pg/mL) to 96 pg/mL (25th to 75th percentiles, 61 to 182 pg/mL; Pϭ0.002) and remained low at follow-up (Figure 1 ). Systolic and diastolic blood pressures decreased from baseline values of 172Ϯ18 and 89Ϯ13 mm Hg before intervention to 144Ϯ24 and 72Ϯ12 mm Hg after renal stent placement at 3.5Ϯ1.3 months of follow-up (range, 2 to 7 months) (PϽ0.001 for both systolic and diastolic blood pressures). The number of antihypertensive medications decreased from 3.8Ϯ0.8 before intervention to 3.2Ϯ1 at follow-up (Pϭ0.02). For the entire group, hypertension improved in 70% of the patients (19 of 27) at hospital discharge. Blood pressure improvement was sustained in 63% of patients (17 of 27) at 3.5Ϯ1.3 months of follow-up.
Twenty-two patients (81%) with renal artery stenosis had a baseline BNP Ͼ80 pg/mL. In this group, hypertension improvement occurred in 77% of the patients (nϭ17) compared with 0% of the 5 patients with a baseline BNP Յ80 pg/mL (Pϭ0.001) (Figure 2 ). The sensitivities, specificities, and positive and negative predictive values of using a baseline BNP Ͼ80 pg/mL to predict hypertension improvement at 3.5Ϯ1.3 months of follow-up were 100%, 50%, 77%, and 100%, respectively. After renal stent placement, BNP decreased by Ͼ30% of the baseline value in 17 patients (63%). In those patients whose posttreatment BNP fell by Ͼ30%, blood pressure improved at follow-up in 94% (16 of 17 patients). In patients whose BNP fell by Յ30%, only 1 patient (10%) had improved blood pressure (PϽ0.001) (Figure 2 ). After renal stent placement, there was a significantly greater decrease in BNP in blood pressure responders compared with blood pressure nonresponders (Figure 3 ).
Influence of GFR and Severity of Renal Artery Stenosis
Fifteen patients had eGFR Ն60 mL · Table 2 . We found no correlation between the severity of the renal artery stenosis and preprocedural BNP levels (as a continuous variable) (Pϭ0.51), BNP Ͼ80 pg/mL (as a categorical variable) (Pϭ0.30), or blood pressure response (Pϭ0.24).
Blood Pressure Responders Versus Nonresponders
The baseline clinical characteristics, including the BNP and eGFR before and after intervention, for blood pressure responders compared with nonresponders are shown in Table  3 . Six blood pressure responders (35%) and 3 nonresponders (30%) had bilateral renal artery stenosis (Pϭ0.56). Blood pressure responders after renal stent placement had a higher preprocedural diastolic blood pressure and lower eGFR. Additionally, blood pressure responders were more likely to have an elevated baseline BNP (Ͼ80 pg/mL).
There was a good correlation between baseline BNP Ͼ80 pg/mL, postprocedural BNP drop, and GFR with blood pressure response to treatment (Table 4) . Using a multivariate correlation analysis, we found that preprocedural BNP 
Discussion
We have demonstrated that BNP is increased in patients with refractory hypertension and renal artery stenosis and that this peptide may be useful for predicting which patients will have clinically improved blood pressure after successful renal revascularization. Patients with clinical evidence of congestive heart failure or an acute coronary syndrome were excluded, so the baseline elevation of BNP in our study patients cannot be attributed to these conditions. The significant decline in BNP after renal artery revascularization strongly suggests a cause-and-effect relationship for renal artery stenosis and BNP elevation. Identifying patients who are likely to have blood pressure improvement after renal revascularization is important for clinicians, because 20% to 40% of patients with refractory hypertension and renal artery stenosis do not have a blood pressure reduction after renal revascularization. 2 BNP plays an important role in renal physiology. It increases the GFR, promotes natriuresis, and antagonizes the renin-angiotensin-aldosterone system. 3 The main source of circulating BNP is the ventricular myocardium. However, BNP has also been shown to be synthesized and released from glomerular mesangial and epithelial cells. 23 Renal artery stenosis induces the activation of the renin-angiotensin system with increased levels of angiotensin II. [15] [16] [17] Recent animal data have shown that angiotensin II directly stimulates the synthesis and release of BNP independently of cell stretching 13 and that the mRNA for both atrial natriuretic peptide (ANP) and BNP is upregulated in the 2-kidney, 1-clip renal artery stenosis model. 14 Our data support the results of these experimental studies in that we found an elevated BNP (Ͼ80 pg/mL) in 81% (22 of 27) of our hypertensive patients with renal artery stenosis. BNP may represent a biochemical marker for activation of the renin-angiotensin system and thus may be a useful clinical assay to help identify patients who will benefit from revascularization.
In agreement with previous studies, eGFR increased only in patients with bilateral renal artery stenosis after stent revascularization. In unilateral renal artery stenosis, the unobstructed kidney is capable of compensating for the contralateral stenotic kidney by increasing its GFR. 24, 25 After revascularization, however, the compensatory increase in GFR of the nonobstructed kidney returns to baseline, and the overall GFR remains unaltered. Although BNP has been reported to be elevated in patients with a GFR Ͻ60 mL · min Ϫ1 · 1.73 m Ϫ2 , 26 our data demonstrated no statistical significant difference for elevated BNP (Ͼ80 pg/mL) stratified for an eGFR Ͻ60 or Ͼ60 mL · min Ϫ1 · 1.73 m Ϫ2 (92% versus 67%; Pϭ0.14). We also showed that BNP declines in both groups after revascularization, implying that BNP is a useful assay to predict blood pressure response regardless of the baseline GFR.
Previous investigations have attempted to identify predictors of blood pressure response after revascularization of renal artery stenosis. [27] [28] [29] We have demonstrated a strong correlation between BNP and hypertension improvement that is independent of eGFR, serum creatinine, and baseline blood pressure. An elevated baseline BNP of Ͼ80 pg/mL was a strong predictor of hypertension improvement at follow-up (100% sensitivity, 77% positive predictive value, and 100% negative predictive value), with a specificity of 50%. There was no correlation between severity of the renal artery stenosis on angiography and blood pressure improvement or elevated BNP. Angiography suffers from limited precision when trying to image aorto-ostial renal artery lesions. These vessels arise at unpredictable angles from the aorta and may not be seen well with 2D angiographic imaging. Previous reports have also failed to show this correlation, 27,29 and 1 study found that a reduction in renal cortical perfusion was not directly related to the severity of renal artery stenosis. 30 
Study Limitations
Our study is limited by the relatively small number of patients; the likelihood of a type I statistical error is increased. Because we do not have a control group of refractory hypertensive patients without renal artery stenosis, it remains speculative whether other potential factors such as older age or the presence of coronary artery disease may have contributed to the elevated BNP in this group of patients with renal artery stenosis. [31] [32] [33] 
